MUMBAI, India, July 30 -- Intellectual Property India has published a patent application (202641086812 A) filed by Dr. Kondapuram Parameshwar; Dr B Nagamani; Dr. M. Gayatri Devi; Ms. Aswani Dukka; Ms. A. Suneetha Devi; Ms. P. Sivalalitha; Ms. Renuka Balireddi; Ms. M. Bhagya Sree; and Ms. D. Pavitra on July 15, 2026, for A Novel Bilosomal Vesicular Carrier-Based Pharmaceutical Composition Comprising Dasatinib For Enhanced Transdermal Delivery In The Treatment Of Skin Cancer.
Inventors include Dr. Kondapuram Parameshwar; Dr B Nagamani; Dr. M. Gayatri Devi; Ms. Aswani Dukka; Ms. A. Suneetha Devi; Ms. P. Sivalalitha; Ms. Renuka Balireddi; Ms. M. Bhagya Sree; and Ms. D. Pavitra.
The application for the patent was published on July 24, 2026, under issue no. 30/2026.
Abstract: The present invention relates to a bilosomal vesicular carrier-based pharmaceutical composition comprising Dasatinib or a pharmaceutically acceptable salt thereof for enhanced transdermal delivery in the treatment of skin cancer. Dasatinib exhibits significant anticancer activity; however, its clinical application is limited by poor aqueous solubility, extensive first-pass metabolism, variable oral bioavailability, and systemic adverse effects. The invention provides nanosized Dasatinib-loaded bilosomal vesicles comprising one or more phospholipids, one or more bile salts, one or more non-ionic surfactants, cholesterol, and pharmaceutically acceptable excipients to improve skin permeation, localized drug deposition, and sustained drug release. The bilosomal formulation is prepared by a thin-film hydration technique followed by vesicle size reduction through homogenization and is incorporated into a pharmaceutically acceptable topical gel for transdermal administration. The pharmaceutical composition exhibits improved physicochemical stability, enhanced retention within skin tissues, prolonged localized therapeutic action, and reduced systemic exposure compared with conventional Dasatinib formulations. The invention is useful for the localized treatment of melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin malignancies, providing an effective, non-invasive, and patient-friendly transdermal drug delivery system.
Disclaimer: Curated by HT Syndication.
